SCHEMBL7737872

SCHEMBL7737872

CCCCNc1ncccc1C(=O)c1cccc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.49
MEN1 O00255 5/20 0.49
PKM P14618 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MAPT P10636 4/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
VNN1 O95497 3/20 0.47
MTNR1B P49286 1/20 0.46
CHRNA7 P36544 2/20 0.45
POLB P06746 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
DHODH Q02127 1/20 0.43
CES2 O00748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8694860 0.84 KMT2A (0.56) KMT2AMEN1PKMMAPK1HTT
SCHEMBL21336185 0.79 MEN1 (0.65) KMT2AMEN1PKMMAPK1HTT
SCHEMBL7437816 0.79 ALDH1A1 (0.59) KMT2AMEN1PKMHTTALDH1A1
SCHEMBL8569592 0.78 CDK5 (0.53) KMT2AMEN1PKMMAPK1HTT
SCHEMBL8692447 0.76 KDM4E (0.68) KMT2AMEN1HTTALDH1A1HPGD
SCHEMBL15635912 0.76 KDM4E (0.62) KMT2AMEN1PKMMAPK1HTT
SCHEMBL7369720 0.76 ELANE (0.49) KMT2AMEN1PKMMAPK1HTT
SCHEMBL5365864 0.75 CES2 (0.51) KMT2AMEN1PKMMAPK1HTT
SCHEMBL28747256 0.75 CES2 (0.51) KMT2AMEN1PKMMAPK1HTT
SCHEMBL7370589 0.74 ALDH1A1 (0.55) KMT2AMEN1PKMMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK KMT2A 578/4885MEN1 1602/4885PKM 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.